Down-Regulation of Mcl-1 by Small Interference RNA Induces Apoptosis and Sensitizes HL-60 Leukemia Cells to Etoposide |
Karami, Hadi
(Immunology Research Center, Department of Medical Immunology, Faculty of Medicine, Tabriz University of Medical Sciences)
Baradaran, Behzad (Immunology Research Center, Department of Medical Immunology, Faculty of Medicine, Tabriz University of Medical Sciences) Esfehani, Ali (Hematology and Oncology Research Center, Shahid Ghazi Hospital, Tabriz University of Medical Sciences) Sakhinia, Masoud (Faculty of Medicine, University of Liverpool) Sakhinia, Ebrahim (Tuberculosis and Lung Diseases Research Centre, Department of Medical Genetics, Faculty of Medicine, Tabriz Genetic Analysis Centre, Tabriz University of Medical Sciences) |
1 | Yang M, Mattes J (2008). Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther, 117, 94-104. DOI ScienceOn |
2 | Yecies D, Carlson NE, Deng J, Letai A (2010). Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood, 115, 3304-13. DOI ScienceOn |
3 | Zhang S, Li G, Ma X, et al (2012). Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal, 24, 1803-9. DOI ScienceOn |
4 | Reischl D, Zimmer A (2009). Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine, 5, 8-20. DOI ScienceOn |
5 | Robak T, WierzbowskaI A (2009). Current and emerging therapies for acute myeloid leukemia. Clin Ther, 31, 2349-70. DOI ScienceOn |
6 | Shan G (2010). RNA interference as a gene knockdown technique. Int J Biochem Cell Biol, 42, 1243-51. DOI ScienceOn |
7 | Skoda C, Erovic BM, Wachek V, et al (2008). Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncol Rep, 19, 1499-503. |
8 | Szer J (2012). The prevalent predicament of relapsed acute myeloid leukemia. Hematol Am Soc Hematol Educ Program, 2012, 43-8. |
9 | Thallinger C, Wolschek MF, Maierhofer H, et al (2004). Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res, 10, 4185-91. DOI ScienceOn |
10 | Thallinger C, Woschek MF, Wacheck V, et al (2003). Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol, 120, 1081-6. DOI ScienceOn |
11 | Warr MR, Shore GC (2008). Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med, 8, 138-47. DOI ScienceOn |
12 | Xiao J, Yin S, Li Y, et al (2009). SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells. Acta Biochim Biophys Sin, 41, 699-708. DOI ScienceOn |
13 | Kupsa T, Horacek JM, Jebavy L (2012). The role of cytokines in acute myeloid leukemia: a systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 156, 291-301. |
14 | Kano R, Yano T, Nagamatsu K, et al (2009). Effectiveness of small interfering RNA (siRNA) against the Mcl-1 gene in a canine mammary gland tumor cell line. Res Vet Sci, 87, 64-6. DOI ScienceOn |
15 | Kaufmann SH, Karp JE, Svingen PA, et al (1998). Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood, 91, 991-1000. |
16 | Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW (1993). MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A, 90, 3516-20. DOI ScienceOn |
17 | Li G, Chang H, Zhai YP, Xu W (2013). Targeted silencing of inhibitors of apoptosis proteins with siRNAs: a potential anti-cancer strategy for hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 4943-52. 과학기술학회마을 DOI ScienceOn |
18 | LivakI KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2- Method. Methods, 25, 402-8. DOI ScienceOn |
19 | Quinn BA, Dash R, Azab B, et al (2011). Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs, 20, 1397-411. DOI ScienceOn |
20 | Montecucco A, Biamonti G (2007). Cellular response to etoposide treatment. Cancer Lett, 252, 9-18. DOI ScienceOn |
21 | Ramachandran PV, Ignacimuthu S (2012). RNA interference as a plausible anticancer therapeutic tool. Asian Pac J Cancer Prev, 13, 2445-52. 과학기술학회마을 DOI ScienceOn |
22 | David S, Pitard B, Benoit JP, Passirani C (2010). Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res, 62, 100-14. DOI ScienceOn |
23 | Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A (2009). MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol, 187, 429-42. DOI ScienceOn |
24 | Chetoui N, Sylia K, Gagnon-Houde JV, et al (2008). Downregulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res, 6, 42-52. DOI ScienceOn |
25 | Chou TC, Talaly P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55. DOI ScienceOn |
26 | Glaser SP, Lee EF, Trounson E, et al (2012). Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev, 26, 120-5. DOI ScienceOn |
27 | Han P, Luan Y, Lin Y, et al (2013). Small interfering RNA targeting Rac1 sensitizes colon cancer to dihydroartemisinininduced cell cycle arrest and inhibited cell migration by suppressing NFkappaB activity. Mol Cell Biochem, 379, 171-80. DOI ScienceOn |
28 | Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG (2012). Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther, 20, 513-24. DOI |
29 | High LM, Szymanska B, WilczynskaI-Kalak U, et al (2010). The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol, 77, 483-94. DOI ScienceOn |
30 | Hussain SR, Cheney CM, Johnson AJ, et al (2007). Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximabmediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res, 13, 2144-50. DOI ScienceOn |
31 | Akagi H, Higuchi H, Sumimoto H, et al (2013). Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapyassociated apoptosis in gastric cancer cells. Gastric Cancer, 16, 100-10. DOI ScienceOn |
32 | Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE (2009). Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res, 7, 549-56. DOI ScienceOn |
33 | Martins LM, Mesner PW, Kottke TJ, et al (1997). Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90, 4283-96. |
34 | Smits EL, Berneman ZN, Van Tendeloo VF (2009). Immunotherapy of acute myeloid leukemia: current approaches. Oncologist, 14, 240-52. DOI ScienceOn |